This event is now closed, information is displayed here for information only.

The 2017 ‘Frontiers of Oncology: Haematology’ meeting will be announced in January 2017

but you can pre-register HERE to be advised when the programme is released

 

A one day meeting held on
Monday 19th September 2016
The Royal College of Physicians, London, UK

---

Chairs

Professor Mark Emberton Professor of Interventional Oncology UCL Cancer Institute

Dr Mark Linch Medical Oncology Consultant University College London Hospital

---

From 08.00	Registration & Coffee
09.00	Welcome / setting the scene: The Chairmen
	Morning Sessions: The Prostate SESSION 1: Early Detection & Diagnostics
09.05	Introduction from session Chair: Professor Mark Emberton
09.10	MRI in prostate cancer detection Dr Clare Allen Consultant Radiologist, UCLH, London, UK
09.35	Understanding biomarkers when diagnosing prostate cancer Dr Hayley Whitaker Head of the Centre for Molecular Intervention, UCL, London, UK
10.00	Biopsies in prostate cancer Dr Hashim Ahmed Reader in Surgical Uro-oncology, Research Department of Urology, UCL, London, UK
10.25	Discussion of merits and demerits of above findings Chairman & Speakers
10.40	Break
	SESSION 2: Multidisciplinary Team Educational Session
11.10	Chair: Professor Mark Emberton
	Image based personalised active surveillance Dr Caroline Moore Senior Clinical Researcher & Honorary Consultant Urological Surgeon, UCL & UCLH, London, UK
	Tissue selective surgery Dr Hashim Ahmed Reader in Surgical Uro-oncology, Research Department of Urology, UCL, London, UK
	Tissue selective surgery Professor John Kelly Professor of Uro-Oncology, UCLH, London, UK
	Radiotherapy Dr Anita Mitra Consultant Clinical Oncologist, University College London Hospitals, London, UK
12.10	Keynote Presentation Reflections on diagnosis and treatment: Patients’ perspectives Professor Jan van der Meulen Professor of Clinical Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
12.30	Lunch
	Afternoon Sessions: Beyond the Prostate SESSION 3: Metastatic Disease
13.30	Introduction from session Chair: Dr Mark Linch
13.35	Hormones Professor Heather Payne Consultant Clinical Oncologist, University College London Hospitals, London, UK
14.00	Chemotherapy Dr Ursula McGovern Consultant Medical Oncologist, University College London Hospitals, London, UK
14.25	Novel therapies Dr Mark Linch Consultant Medical Oncologist & Honorary Senior Lecturer, University College London Hospitals, London, UK
14.50	Discussion of merits and demerits of above findings Chairman & Presenters
15.05	Break
15.35	Keynote Presentation Opportunities for immunotherapies in urology Dr Sergio Quezada Group Leader – Immune Regulation and Tumor Immunotherapy Lab, UCL Cancer Institute, London, UK
	SESSION 4: Multidisciplinary Team Educational Session Management of Symptomatic Metastatic Prostate Cancer
16.05	Introduction from session Chair: Dr Mark Linch
	Radiotherapy Professor Heather Payne Consultant Clinical Oncologist, University College London Hospitals, London, UK
	Chemotherapy Dr Ursula McGovern Consultant Medical Oncologist, University College London Hospitals, London, UK
	EndoUrology Mr Daron Smith Consultant Urological Surgeon, University College London Hospitals, London, UK
	Palliative care Professor Paddy Stone Marie Curie Chair in Palliative and End of Life Care, University College London, UK
	Uro-Oncology CNS Janet Forgenie Uro-Oncology Clinical Nurse Specialist, University College London Hospitals, London, UK
17.05	Summary & Close

This meeting is organised by:

 

and endorsed and supported by:

---

The Frontiers of Oncology 2019 meetings are supported by the Pharmaceutical Industry.
As support agreements are reached, disclosure of the supporters is listed here.